NSCLC (Non-small Cell Lung Carcinoma) Withdrawn Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0103105 (NSCLC (Non-small Cell Lung Carcinoma))Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02355431Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsTreatment